Nursing practice questions with comprehensive rationales
NurseDive Free Nursing Practice Question
What is a common sign of digoxin toxicity?
A. Vomiting.
Vomiting is a common sign of digoxin toxicity. It occurs due to the drug's effects on the gastrointestinal system, which can lead to nausea and vomiting as the body attempts to expel the toxin. This symptom is particularly significant as it can indicate elevated digoxin levels that may require medical intervention.
B. Tachycardia.
Tachycardia, or an increased heart rate, can occur with digoxin toxicity; however, it is more commonly associated with inadequate therapeutic levels rather than toxicity itself. Digoxin usually causes bradycardia (a slower heart rate) when at therapeutic levels, making tachycardia less indicative of toxicity.
C. Bradypnea.
Bradypnea (slow breathing) is not a common sign of digoxin toxicity. While digoxin primarily affects the heart, it doesn't typically have a direct impact on respiratory function.
D. Seizures.
Seizures are not a common sign of digoxin toxicity. Digoxin toxicity primarily affects the heart's electrical activity and can lead to arrhythmias, but it doesn't typically cause seizures.
This question is an excerpt from Nurse Dive's nursing test bank - Pediatrics Midterm V1 2023 Test 3 Proctored Exam. Take the full exam now
Full Explanation
The correct answer is Choice A.Choice A rationale: Vomiting is a common sign of digoxin toxicity. It occurs due to the drug's effects on the gastrointestinal system, which can lead to nausea and vomiting as the body attempts to expel the toxin. This symptom is particularly significant as it can indicate elevated digoxin levels that may require medical intervention.Choice B rationale: Tachycardia, or an increased heart rate, can occur with digoxin toxicity; however, it is more commonly associated with inadequate therapeutic levels rather than toxicity itself. Digoxin usually causes bradycardia (a slower heart rate) when at therapeutic levels, making tachycardia less indicative of toxicity.Choice C rationale: Bradypnea, or slow breathing, is not a typical sign of digoxin toxicity. While respiratory issues can arise from various conditions, they are not specifically linked to digoxin levels. Monitoring respiratory rate is essential in clinical settings but does not directly correlate with digoxin toxicity.Choice D rationale: Seizures are not a common sign of digoxin toxicity. While severe cases might lead to neurological symptoms due to electrolyte imbalances or other complications, seizures are not typically associated with digoxin overdose. Instead, they may suggest other underlying issues requiring evaluation.
Similar Questions
What is a common clinical manifestation of juvenile hypothyroidism?
A. Diarrhea.
Diarrhea is not a common clinical manifestation of juvenile hypothyroidism. Hypothyroidism is characterized by an underactive thyroid gland, leading to a decrease in metabolic activity. Symptoms of hypothyroidism include fatigue, weight gain, cold intolerance, constipation, and dry skin, but not diarrhea.
B. Dry skin.
Dry skin is a common clinical manifestation of juvenile hypothyroidism. The decreased thyroid function results in a slower metabolic rate, which can lead to dry and coarse skin due to reduced oil production. This symptom is often seen in hypothyroid patients.
C. Insomnia.
Insomnia is not a common clinical manifestation of juvenile hypothyroidism. Hypothyroidism usually leads to fatigue and excessive sleepiness rather than insomnia.
D. Accelerated growth.
Accelerated growth is not a common clinical manifestation of juvenile hypothyroidism. In fact, the opposite is true. Hypothyroidism in children can lead to growth retardation due to the decreased metabolic rate and altered hormonal balance.
Full Explanation
The correct answer is Choice B: Dry skin.
Choice A rationale:
Diarrhea is not a common clinical manifestation of juvenile hypothyroidism. Hypothyroidism is characterized by an underactive thyroid gland, leading to a decrease in metabolic activity. Symptoms of hypothyroidism include fatigue, weight gain, cold intolerance, constipation, and dry skin, but not diarrhea.
Choice B rationale:
Dry skin is a common clinical manifestation of juvenile hypothyroidism. The decreased thyroid function results in a slower metabolic rate, which can lead to dry and coarse skin due to reduced oil production. This symptom is often seen in hypothyroid patients.
Choice C rationale:
Insomnia is not a common clinical manifestation of juvenile hypothyroidism. Hypothyroidism usually leads to fatigue and excessive sleepiness rather than insomnia.
Choice D rationale:
Accelerated growth is not a common clinical manifestation of juvenile hypothyroidism. In fact, the opposite is true. Hypothyroidism in children can lead to growth retardation due to the decreased metabolic rate and altered hormonal balance.
Therapeutic management of most children with Hirschsprung's disease is primarily
A. surgical removal of the affected section of bowel.
Surgical removal of the affected section of bowel is the primary therapeutic management for most children with Hirschsprung's disease. Hirschsprung's disease is a congenital condition where there is a lack of nerve cells in a segment of the colon, leading to obstruction and dilation of the bowel. Surgical resection of the affected segment and reconnection of healthy bowel portions is the standard treatment to alleviate the obstruction and restore normal bowel function.
B. daily enemas.
Daily enemas might be used in some cases to manage symptoms temporarily, but they are not the primary therapeutic management for Hirschsprung's disease. Surgery is the mainstay of treatment.
C. permanent colostomy.
Permanent colostomy might be considered if the affected portion of bowel is extensive and cannot be safely reconnected after resection, but it's not the primary option for most children with Hirschsprung's disease.
D. low-fiber diet.
A low-fiber diet is not a therapeutic management for Hirschsprung's disease. Surgical intervention is necessary to address the underlying cause of obstruction, and diet modifications alone wouldn't resolve the condition.
Full Explanation
The correct answer is Choice A: Surgical removal of the affected section of bowel.
Choice A rationale:
Surgical removal of the affected section of bowel is the primary therapeutic management for most children with Hirschsprung's disease. Hirschsprung's disease is a congenital condition where there is a lack of nerve cells in a segment of the colon, leading to obstruction and dilation of the bowel. Surgical resection of the affected segment and reconnection of healthy bowel portions is the standard treatment to alleviate the obstruction and restore normal bowel function.
Choice B rationale:
Daily enemas might be used in some cases to manage symptoms temporarily, but they are not the primary therapeutic management for Hirschsprung's disease. Surgery is the mainstay of treatment.
Choice C rationale:
Permanent colostomy might be considered if the affected portion of bowel is extensive and cannot be safely reconnected after resection, but it's not the primary option for most children with Hirschsprung's disease.
Choice D rationale:
A low-fiber diet is not a therapeutic management for Hirschsprung's disease. Surgical intervention is necessary to address the underlying cause of obstruction, and diet modifications alone wouldn't resolve the condition.
Instructions for decongestant nose drops should include what recommendation?
A. Avoiding use for more than 3 days.
Recommending avoiding the use of decongestant nose drops for more than 3 days is crucial due to the risk of rebound congestion. Decongestant nose drops work by constricting blood vessels in the nasal passages to alleviate congestion. Prolonged use can lead to a phenomenon known as rebound congestion, where the nasal passages become more congested once the medication wears off, causing the person to use the drops more frequently. This can result in a cycle of worsening congestion and overuse of the medication, which can be counterproductive and harmful. Limiting the use of decongestant nose drops to 3 days helps prevent this rebound effect and encourages the use of alternative treatments if congestion persists.
B. Administering drops until nasal congestion subsides.
Administering drops until nasal congestion subsides is not the recommended approach. Prolonged use of decongestant nose drops can lead to rebound congestion, as mentioned earlier. Using the drops until congestion subsides might extend their use beyond the safe period and increase the risk of adverse effects.
C. Keeping drops to use again for nasal congestion.
Keeping drops to use again for nasal congestion is not advised. While it's important to follow the medication's storage instructions, relying on decongestant nose drops for recurring nasal congestion can lead to overuse and rebound congestion. This choice does not address the potential risks associated with prolonged use.
D. Administering drops after feedings and at bedtime.
Administering drops after feedings and at bedtime is not a standard recommendation for decongestant nose drops. The timing of administration is not a primary concern in the context of decongestant use. Instead, the focus should be on the duration of use and the potential for rebound congestion.
Full Explanation
The correct answer is choice A: Avoiding use for more than 3 days.
Choice A rationale:
Recommending avoiding the use of decongestant nose drops for more than 3 days is crucial due to the risk of rebound congestion. Decongestant nose drops work by constricting blood vessels in the nasal passages to alleviate congestion. Prolonged use can lead to a phenomenon known as rebound congestion, where the nasal passages become more congested once the medication wears off, causing the person to use the drops more frequently. This can result in a cycle of worsening congestion and overuse of the medication, which can be counterproductive and harmful. Limiting the use of decongestant nose drops to 3 days helps prevent this rebound effect and encourages the use of alternative treatments if congestion persists.
Choice B rationale:
Administering drops until nasal congestion subsides is not the recommended approach. Prolonged use of decongestant nose drops can lead to rebound congestion, as mentioned earlier. Using the drops until congestion subsides might extend their use beyond the safe period and increase the risk of adverse effects.
Choice C rationale:
Keeping drops to use again for nasal congestion is not advised. While it's important to follow the medication's storage instructions, relying on decongestant nose drops for recurring nasal congestion can lead to overuse and rebound congestion. This choice does not address the potential risks associated with prolonged use.
Choice D rationale:
Administering drops after feedings and at bedtime is not a standard recommendation for decongestant nose drops. The timing of administration is not a primary concern in the context of decongestant use. Instead, the focus should be on the duration of use and the potential for rebound congestion.